Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Asset Writedowns and Impairment: 2021-2024

Historic Asset Writedowns and Impairment for GeneDx Holdings (WGS) over the last 4 years, with Dec 2024 value amounting to $180,000.

  • GeneDx Holdings' Asset Writedowns and Impairment was N/A to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $180,000 for FY2024, which is 98.27% down from last year.
  • Per GeneDx Holdings' latest filing, its Asset Writedowns and Impairment stood at $180,000 for FY2024, which was down 98.27% from $10.4 million recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' Asset Writedowns and Impairment ranged from a high of $210.1 million in FY2022 and a low of $180,000 during FY2024.
  • In the last 3 years, GeneDx Holdings' Asset Writedowns and Impairment had a median value of $10.4 million in 2023 and averaged $73.6 million.
  • In the last 5 years, GeneDx Holdings' Asset Writedowns and Impairment skyrocketed by 9,770.60% in 2022 and then tumbled by 98.27% in 2024.
  • Yearly analysis of 4 years shows GeneDx Holdings' Asset Writedowns and Impairment stood at $2.1 million in 2021, then spiked by 9,770.60% to $210.1 million in 2022, then crashed by 95.05% to $10.4 million in 2023, then slumped by 98.27% to $180,000 in 2024.